Laboratorial evolution of multifactorial cholestasis in pediatric patients
DOI:
https://doi.org/10.11606/issn.1679-9836.v98i5p309-314Keywords:
Cholestasis, Jaundice, neonatal, Infant, newbornAbstract
Introduction: In the immature liver of the newborn (RN) neonatal cholestasis can occurs in association with several risk factors, with no underlying pathology. This condition is called transient multifactorial neonatal cholestasis. Prematurity, intrauterine growth restriction or situations that lead to increased oxidative stress (ischemia, hemodynamic compromise, infections, surgical interventions, food pause, intravenous nutrition and drugs) are related to its genesis. Objective: to assess the evolution of neonatal cholestasis in the multifactorial period, as well as to verify the mean changes in liver enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and canalicular, gammaglutamyltransferase (GGT) and direct bilirubin (BD), comparing the duration of cholestasis in patients who used ursodeoxycholic acid with the time of evolution of those who did not, in order to better characterize this clinical condition and to draw the attention of the health professional about its transient nature, thus avoiding the request for more specific, expensive, and unnecessary exams. Methods: A cross-sectional study with 32 patients from zero to 90 days who presented with neonatal multifactorial cholestasis, accompanied in the ambulatory of pediatric hepatology of IMIP, from August 2016 to August 2017. Data were collected through medical records. The analysis of the data was performed using software “R” v.3.3.1. Results: The majority of the patients were male (59.38%). The mean age of onset of cholestasis was 35.5 days, and the mean age of onset was 171 days. The mean duration of cholestasis was 135.8 days. The mean BD value of the onset and end of cholestasis was 6.05 and 0.29 mg/dL, respectively. In relation to liver and canalicular enzymes, the mean values of AST, ALT and GGT at baseline were 194.7, 123.8 and 387.9 U/L, and the mean values of 69.1, 56.0 and 121.6U/L, respectively. Only 11 patients used ursodeoxycholic acid (UDCA). The mean duration of cholestasis in this group was 114.1 days. Those who did not use the UDCA, 21 patients, presented cholestatic jaundice for a mean time of 147.1 days. Conclusion: In view of the results obtained with the retrospective analysis of patients with a diagnosis of multifactorial cholestasis, the transient and benign nature of this clinical condition is noted, with a mean duration of cholestasis around 136 days of life and with an important decrease in liver enzyme levels after resolution of the condition
Downloads
References
Tufano M, Nicastro E, Giliberti P, Vegnente A, Raimondi F, Iorio R. Cholestasis in neonatal intensive care unit: Incidence, aetiology and management. Acta Paediatr. 2009;98(11):1756-61. doi: 10.1111/j.1651-2227.2009.01464.x.
Silva ES, Pó I, Gonçalves I. Colestase neonatal – protocolo de abordagem diagnóstica. Acta Pediatr Port. 2010;41(3):141-3.
Loomes KM, Erlichman J. Approach to evaluation of cholestasis in neonates and young infants. UpToDate. 2017 Jun [cited 2017 July 27]. Available from: https://www.uptodate.com/contents/approach-to-evaluation-of-cholestasis-in-neonates-and-young-infants?source=search_result&search=Definition%20of%20multifactorial%20cholestasis&selectedTitle=1~150
Best C, Gourley GR. Management of neonatal cholestasis. Therapy. 2009;6(1):75-81. https://doi.org/10.2217/14750708.6.1.75.
Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, Karpen S, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2017;64(1):154-68. doi: 10.1097/MPG.0000000000001334.
Carreira MSP. Fisiopatologia e fatores de risco associados ao desenvolvimento de colestase no período neonatal [dissertação]. Porto: Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto; 2014. Disponível em: https://pdfs.semanticscholar.org/0d33/e4df3e43154aa99f2280132187a47b7a47b5.pdf.
Pinto R, Silveira TR. Colestase neonatal: uma abordagem prática. Bol Cient Pediatr. 2016;05(3):92-102. Disponível em: http://www.sprs.com.br/sprs2013/bancoimg/170118174030bcped_05_03_a05.pdf.
Carvalho E, Ivantes CAP, Bezerra JA. Atresia das vias biliares extra-hepáticas: conhecimentos atuais e perspectivas futuras. J Pediatr. 2007;83(2):105-20. https://dx.doi.org/10.2223/JPED.1607.
Nazer H. Cholestasis Treatment & Management. 2017 Aug [cited 2017 Oct 27]. In: Medscape. Available from: https://emedicine.medscape.com/article/927624-treatment
Albers M, de Gast-Bakker D, van Dam N, Madern G, Tibboel D. Male sex predisposes the newborn surgical patient to parenteral nutrition-associated cholestasis and to sepsis. Arch Surg. 2002;137(7):789-93. doi: 10.1001/archsurg.137.7.789.
Simões AP, Santos MC, Nunes A, Martins M, Bispo MA, Palminha JM. Colestase neonatal: contribuição da clínica e dos exames complementares para o diagnóstico diferencial (dez anos de experiência). Acta Pediatr Port. 1999;30(6):459-66.
Oswari H, Widjaja R, Rohsiswatmo R, Cleghorn G. Prognostic value of biochemical liver parameters in neonatal sepsis-associated cholestasis. J Paediatr Child Health. 2013;49(1):E6-11. doi: 10.1111/jpc.12053.
Repa A, Lochmann R, Unterasinger L, Weber M, Berger A, Haiden N. Aggressive nutrition in extremely low birth weight infants: impact on parenteral nutrition associated cholestasis and growth. PeerJ. 2016;4:e2483. doi: 10.7717/peerj.2483.
Chen C, Tsao P, Chen H, Chou H, Hsieh W, Chang M. Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. J Pediatr. 2004;145(3):317-21. doi: 10.1016/j.jpeds.2004.05.038.
Kim A, Lim R, Han Y, Park K, Byun S. Parenteral nutrition-associated cholestasis in very low birth weight infants: a single center experience. Pediatr Gastroenterol Hepatol Nutr. 2016;19(1):61-70. doi: 10.5223/pghn.2016.19.1.61.
Liu P, Guo L, Huang L, Zhao D, Zhen R, Yuan X, et al. Analysis of factors affecting the prognosis of neonatal cholestasis. Int J Clin Exp Med. 2015; 8(5): 8005-9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509307/.
Lane E, Murray K. Neonatal cholestasis. Pediatr Clin North Am. 2017;64(3):621-39. doi: 10.1016/j.pcl.2017.01.006.
Satrom K, Gourley G. Cholestasis in preterm infants. Clin Perinatol. 2016;43(2):355-73. doi: 10.1016/j.clp.2016.01.012.
Thibault M, McMahon J, Faubert G, Charbonneau J, Malo J, Mohamed I, et al. Parenteral nutrition-associated liver disease: a retrospective study of ursodeoxycholic acid use in neonates. J Pediatr Pharmacol Ther. 2014;19(1):42-8. doi: 10.5863/1551-6776-19.1.42.
